On the other hand, the PACAP ligand mAb, Lu AG09222, was shown to reduce the number of monthly migraine days from baseline to weeks 1–4 of treatment statistically significantly more than placebo [162,163]. This evidence concerns the gene ADCYAP1 and migraine disorder.